Affiliation:
1. From the Departments of Pharmacology (B.M., P.A.D., H.L.J., E.G.E., F.T.) and Anesthesiology (E.G.E., F.T.), University of Illinois College of Medicine at Chicago.
Abstract
Abstract
—Angiotensin I–converting enzyme (ACE, kininase II) has 2 active domains (N and C) in a single peptide chain. Because we found its N-domain more stable than its C-domain, we investigated the effect of the amino-terminus of human ACE on the C-domain with a molecular construct expressed in Chinese hamster ovary cells (CHO) cells and transiently in HEK293 cells. This active N-deleted ACE contained only the first 141 amino acids of the human N-domain but not its active center and was linked to the active C-domain containing the transmembrane and cytosolic portions of ACE. The CHO cells were also transfected with human B
2
bradykinin receptor. ACE inhibitors (5 nmol/L or 1 μmol/L) augmented bradykinin (100 nmol/L) effects, elevated B
2
receptor numbers, and resensitized the receptor desensitized by agonist as measured by arachidonic acid release or [Ca
2+
]
i
mobilization. Arachidonic acid release was mediated by pertussis toxin–sensitive Gα
i
, and [Ca
2+
]
i
mobilization was mediated by pertussis-insensitive Gα
q
protein receptor complex. The properties of the construct were compared with wild-type ACE and separate N- and C-domains. The N-deleted ACE differed from wild-type in activation by Cl
−
and [SO
4
]
2−
ions, hydrolysis ratios of substrates (both short synthetic and endogenous peptides) and heat stability. Thus, the N-terminal peptide of ACE affected the characteristics of the C-domain active center. ACE inhibitors acting on N-deleted ACE, which had only a single C-domain active center anchored to plasma membrane, induced cross-talk between the enzyme and the B
2
receptor (eg, the inhibitors resensitized the receptor) independent of blocking bradykinin inactivation.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献